March 12, 2026
The Washington Post recently published an article featuring Rena Conti, Professor of Markets, Public Policy, and Law, discussing how a rapidly evolving market for GLP-1 weight-loss drugs is driving down prices and reshaping how Americans access prescription medications.
The article highlights a rare trend in pharmaceuticals: falling prices driven by strong competition among drugmakers, widespread cash-paying customers, and the rapid expansion of alternative distribution channels such as telehealth platforms and compounding pharmacies.
As Rena Conti explains, this shift is highly unusual in the U.S. drug market: “Typically, prices go up after launch in the United States among brand name drugs, not go down. It is an unusual dynamic. The preponderance of patients paying out of pocket for these products is actually creating this dynamic where the companies are lowering their list price to compete for cash-paying customers.”
While cash pricing and competition have improved affordability for some consumers, the system remains fragmented, with many patients still facing high out-of-pocket costs and uneven insurance coverage for weight-loss treatments.
